RV3 rotavirus vaccine: Phase I and II clinical trials of a human neonatal rotavirus vaccine for the global community

轮状病毒感染是肠胃炎的主要原因，每年造成60多万5岁以下儿童死亡。尽管澳大利亚目前有两种商业疫苗，但高昂的成本和对副作用风险的担忧阻碍了疫苗的广泛推广。这项研究的目标是开发一种有效的轮状病毒疫苗，给新生儿接种，全球社会负担得起，能够以低廉的价格在发病率和死亡率负担最重的发展中国家推广。

Rotavirus infection is the leading cause of gastroenteritis responsible for over 600,000 deaths each year in children less than 5 years. Although 2 commercial vaccines are now available in Australia, the high cost and concern about the risk of side effects are barriers to widespread vaccine introduction. The goal of this study is to develop an effective rotavirus vaccine, administered to newborns that is affordable for the global community, able to be introduced cheaply in developing countries where the burden of morbidity and mortality is greatest.